Bioray Biotech Co., Ltd (TPEX:7561)

Market Cap	575.43M -29.4%
Revenue (ttm)	222.73M +10.4%
Net Income	32.25M +3,118.6%
EPS	1.09 +3,533.3%
Shares Out	29.59M
PE Ratio	17.84
Forward PE	n/a
Dividend	0.95 (5.56%)
Ex-Dividend Date	Aug 25, 2026

Volume	1,000
Open	17.10
Previous Close	17.10
Day's Range	17.10 - 17.70
52-Week Range	16.25 - 32.10
Beta	0.10
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 19, 2026

About Bioray Biotech

Bioray Biotech Co., Ltd engages in the research, development, production, and sells health foods, immune cell products, and precision testing services in Taiwan. It provides testing services for oncology and immune profile, gut microbiome, and health insights; CIK Immune Cell Therapy; and supplements and micro-pellets, as well as ODM/OEM services. Bioray Biotech Co., Ltd was founded in 2005 and is based in Tainan City, Taiwan.

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2005
• Employees: 76
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 7561

Financial Performance

In 2025, Bioray Biotech's revenue was 222.73 million, an increase of 10.42% compared to the previous year's 201.71 million. Earnings were 32.25 million, an increase of 3118.56%.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Aug 19, 2026

Data Sources Report a data error